<p>Advisory Services Network LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中披露，其在辉瑞公司（NYSE:PFE - 免费报告）的持股在第四季度增加了 3.5%。该基金在季度内购买了额外的 11,502 股后，持有该生物制药公司 339,805 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Advisory Services Network LLC 在辉瑞的持股价值为 9,015,000 美元。</p>
<ul>
<li>关注这两只医疗保健股票，因为摩根大通提升了吉利德的评级</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也调整了对 PFE 的持股。Nordea Investment Management AB 在第四季度将其在辉瑞的股份增加了 36.1%。Nordea Investment Management AB 目前持有 4,071,700 股该生物制药公司的股票，价值 108,002,000 美元，此前在该期间内又收购了 1,080,822 股。Parsons Capital Management Inc. RI 在第四季度将其在辉瑞的持股增加了 118.7%。Parsons Capital Management Inc. RI 目前持有 294,764 股该生物制药公司的股票，价值 7,820,000 美元，此前在上个季度又购买了 159,984 股。Copley Financial Group Inc. 在第三季度购买了辉瑞的新头寸，价值约 577,000 美元。Geode Capital Management LLC 在第三季度将其在辉瑞的持股增加了 1.6%。Geode Capital Management LLC 目前持有 117,666,245 股该生物制药公司的股票，价值 3,392,342,000 美元，此前在该期间内又购买了 1,855,419 股。最后，Mcdonald Partners LLC 在第四季度将其在辉瑞的持股增加了 9.9%。Mcdonald Partners LLC 目前持有 110,296 股该生物制药公司的股票，价值 2,926,000 美元，此前在该期间内又购买了 9,963 股。68.36% 的股票由机构投资者持有。</p>
<h2>辉瑞价格表现</h2>
<p>辉瑞股票周三开盘价为 21.75 美元。该公司的市值为 1233.3 亿美元，市盈率为 15.42，PEG 比率为 0.64，贝塔值为 0.67。该公司的速动比率为 0.73，流动比率为 1.00，债务股本比率为 0.63。该股票的 50 日简单移动平均线为 25.59 美元，200 日简单移动平均线为 26.58 美元。辉瑞公司的 52 周低点为 21.19 美元，52 周高点为 31.54 美元。</p>
<ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 2 月 4 日星期二发布了季度财报。这家生物制药公司报告该季度每股收益为 0.63 美元，超出分析师一致预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司该季度的收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。在去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 24.7%。整体来看，分析师预计辉瑞公司在当前财政年度的每股收益将达到 2.95。</p>
<h2>分析师升级和降级</h2>
<p>一些股票分析师最近对 PFE 股票发布了报告。Truist Financial 将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并在 12 月 18 日的研究报告中对该股票给予了 “买入” 评级。Guggenheim 在 3 月 18 日的研究报告中重申了对辉瑞股票的 “买入” 评级。美国银行在 12 月 10 日的研究报告中重申了 “中性” 评级，并将辉瑞股票的目标价设定为 29.00 美元。高盛集团在周二的研究报告中重申了 “中性” 评级，并将辉瑞股票的目标价设定为 25.00 美元（从 32.00 美元下调）。最后，汇丰全球研究在 3 月 10 日的研究报告中将辉瑞股票的评级提升至 “强力买入”。一位投资分析师对该股票给予了卖出评级，八位分析师给予了持有评级，六位分析师给予了买入评级，三位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，辉瑞目前的平均评级为 “适度买入”，共识目标价为 31.07 美元。</p>
<ul>
<li>这些股票的收益未达预期，但下个季度将反弹</li>
</ul>
<p><strong>查看我们对 PFE 的最新分析</strong></p>
<h2>内部买入和卖出</h2>
<p>在相关消息中，董事 Ronald E. Blaylock 于 2 月 13 日星期四购买了 19,457 股该公司的股票。每股平均价格为 25.65 美元，总交易额为 499,072.05 美元。购买后，该董事现在直接持有 27,707 股公司股票，价值 710,684.55 美元。此交易代表其持股增加了 235.84%。该购买在向证券交易委员会的文件中披露，相关文件可通过此链接获取。公司内部人士持有 0.06% 的股票。</p>
<h2>关于辉瑞</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>纽约证券交易所和纳斯达克的区别，以及这对投资者的重要性</li>
<li>抗关税股票：三只具有巨大上涨潜力的大便宜股</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>高通股价下跌，但相对强弱指数显示其严重超卖</li>
<li>三只股票引领迷因股复兴</li>
<li>特斯拉的头号看涨者下调目标价，但仍表示值得购买</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>Advisory Services Network LLC 在第四季度将其在辉瑞公司（NYSE:PFE）的持股增加了 3.5%，额外购买了 11,502 股，使其总持股达到 339,805 股，价值 9,015,000 美元。其他机构投资者也增加了在辉瑞的持仓。该股票开盘价为 21.75 美元，市值为 1233.3 亿美元。辉瑞报告的季度每股收益为 0.63 美元，超出预期，分析师预计财年的每股收益为 2.95 美元。该股票的共识评级为 “适度买入”，目标价格为 31.07 美元</p>

<p>Advisory Services Network LLC lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 3.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 339,805 shares of the biopharmaceutical company's stock after purchasing an additional 11,502 shares during the quarter. Advisory Services Network LLC's holdings in Pfizer were worth $9,015,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Advisory Services Network LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中披露，其在辉瑞公司（NYSE:PFE - 免费报告）的持股在第四季度增加了 3.5%。该基金在季度内购买了额外的 11,502 股后，持有该生物制药公司 339,805 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Advisory Services Network LLC 在辉瑞的持股价值为 9,015,000 美元。</p>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>关注这两只医疗保健股票，因为摩根大通提升了吉利德的评级</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Nordea Investment Management AB lifted its stake in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI raised its holdings in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after purchasing an additional 159,984 shares during the last quarter. Copley Financial Group Inc. bought a new position in Pfizer during the third quarter valued at approximately $577,000. Geode Capital Management LLC grew its position in Pfizer by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock worth $3,392,342,000 after purchasing an additional 1,855,419 shares during the period. Finally, Mcdonald Partners LLC grew its position in Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after purchasing an additional 9,963 shares during the period. 68.36% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也调整了对 PFE 的持股。Nordea Investment Management AB 在第四季度将其在辉瑞的股份增加了 36.1%。Nordea Investment Management AB 目前持有 4,071,700 股该生物制药公司的股票，价值 108,002,000 美元，此前在该期间内又收购了 1,080,822 股。Parsons Capital Management Inc. RI 在第四季度将其在辉瑞的持股增加了 118.7%。Parsons Capital Management Inc. RI 目前持有 294,764 股该生物制药公司的股票，价值 7,820,000 美元，此前在上个季度又购买了 159,984 股。Copley Financial Group Inc. 在第三季度购买了辉瑞的新头寸，价值约 577,000 美元。Geode Capital Management LLC 在第三季度将其在辉瑞的持股增加了 1.6%。Geode Capital Management LLC 目前持有 117,666,245 股该生物制药公司的股票，价值 3,392,342,000 美元，此前在该期间内又购买了 1,855,419 股。最后，Mcdonald Partners LLC 在第四季度将其在辉瑞的持股增加了 9.9%。Mcdonald Partners LLC 目前持有 110,296 股该生物制药公司的股票，价值 2,926,000 美元，此前在该期间内又购买了 9,963 股。68.36% 的股票由机构投资者持有。</p>
</div><h2>Pfizer Price Performance</h2>
<div class="lb-trans"><h2>辉瑞价格表现</h2>
</div><p>Shares of Pfizer stock opened at $21.75 on Wednesday. The company has a market capitalization of $123.33 billion, a price-to-earnings ratio of 15.42, a PEG ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's 50-day simple moving average is $25.59 and its 200-day simple moving average is $26.58. Pfizer Inc. has a 52 week low of $21.19 and a 52 week high of $31.54.</p>
<div class="lb-trans"><p>辉瑞股票周三开盘价为 21.75 美元。该公司的市值为 1233.3 亿美元，市盈率为 15.42，PEG 比率为 0.64，贝塔值为 0.67。该公司的速动比率为 0.73，流动比率为 1.00，债务股本比率为 0.63。该股票的 50 日简单移动平均线为 25.59 美元，200 日简单移动平均线为 26.58 美元。辉瑞公司的 52 周低点为 21.19 美元，52 周高点为 31.54 美元。</p>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. The firm's revenue was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 2 月 4 日星期二发布了季度财报。这家生物制药公司报告该季度每股收益为 0.63 美元，超出分析师一致预期的 0.48 美元，超出幅度为 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司该季度的收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。在去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 24.7%。整体来看，分析师预计辉瑞公司在当前财政年度的每股收益将达到 2.95。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>A number of equities analysts have recently issued reports on PFE shares. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, December 18th. Guggenheim reissued a &#34;buy&#34; rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America reaffirmed a &#34;neutral&#34; rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. The Goldman Sachs Group restated a &#34;neutral&#34; rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday. Finally, Hsbc Global Res upgraded shares of Pfizer to a &#34;strong-buy&#34; rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $31.07.</p>
<div class="lb-trans"><p>一些股票分析师最近对 PFE 股票发布了报告。Truist Financial 将辉瑞的目标价从 36.00 美元下调至 32.00 美元，并在 12 月 18 日的研究报告中对该股票给予了 “买入” 评级。Guggenheim 在 3 月 18 日的研究报告中重申了对辉瑞股票的 “买入” 评级。美国银行在 12 月 10 日的研究报告中重申了 “中性” 评级，并将辉瑞股票的目标价设定为 29.00 美元。高盛集团在周二的研究报告中重申了 “中性” 评级，并将辉瑞股票的目标价设定为 25.00 美元（从 32.00 美元下调）。最后，汇丰全球研究在 3 月 10 日的研究报告中将辉瑞股票的评级提升至 “强力买入”。一位投资分析师对该股票给予了卖出评级，八位分析师给予了持有评级，六位分析师给予了买入评级，三位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，辉瑞目前的平均评级为 “适度买入”，共识目标价为 31.07 美元。</p>
</div><ul>
<li>These Stocks Missed on Earnings, But Will Rebound Next Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>这些股票的收益未达预期，但下个季度将反弹</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on PFE</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PFE 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买入和卖出</h2>
</div><p>In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. 0.06% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Ronald E. Blaylock 于 2 月 13 日星期四购买了 19,457 股该公司的股票。每股平均价格为 25.65 美元，总交易额为 499,072.05 美元。购买后，该董事现在直接持有 27,707 股公司股票，价值 710,684.55 美元。此交易代表其持股增加了 235.84%。该购买在向证券交易委员会的文件中披露，相关文件可通过此链接获取。公司内部人士持有 0.06% 的股票。</p>
</div><h2>About Pfizer</h2>
<div class="lb-trans"><h2>关于辉瑞</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Qualcomm Breaks Down But RSI Signals It’s Severely Oversold</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>纽约证券交易所和纳斯达克的区别，以及这对投资者的重要性</li>
<li>抗关税股票：三只具有巨大上涨潜力的大便宜股</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>高通股价下跌，但相对强弱指数显示其严重超卖</li>
<li>三只股票引领迷因股复兴</li>
<li>特斯拉的头号看涨者下调目标价，但仍表示值得购买</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Advisory Services Network LLC Acquires 11,502 Shares of Pfizer Inc. (NYSE:PFE)

- Advisory Services Network LLC 在第四季度增持 Pfizer 股份 3.5%。  
- Nordea Investment Management AB 和 Parsons Capital Management Inc. RI 也分别增持 Pfizer 股份。  
- Pfizer 最新季度收益超出预期，收入同比增长 24.7%。  

Advisory Services Network LLC 收购了辉瑞公司（NYSE:PFE）的 11,502 股股票